Akeso is a biotech headquartered in China. Over the past three years, Akeso has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Licensing, acquisition, and partnership transactions involving Akeso in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| 伊喜寧® (inclisiran injection / 伊努西单抗注射液) | Hubei Jumpcan Pharmaceutical (济川药业) | Antibodies | Approved | license | Feb 3, 2026 |
Therapeutic areas and modalities where Akeso is most active based on deal history and clinical trial data.
Akeso has 50 active clinical trials across 5 development phases.
1
Not Applicable
14
Phase 1
5
Phase 1/2
20
Phase 2
10
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Akeso is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Akeso ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Akeso include Solid Tumors (33 deals and trials), Autoimmune (4 deals and trials), Cardiovascular (2 deals and trials), and CNS Disorders (2 deals and trials). In terms of modality, Akeso has shown particular interest in antibodies, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Akeso and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Akeso's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.